All In Biotech

Drug Trial Radar · NCT06202079

A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

A Phase 2 Clinical Trial Comparing the Efficacy and Safety of Once-weekly GZR4 Injection Versus Once-daily Insulin Degludec in Subjects with Type 2 Diabetes Mellitus on OAD Therapy or OAD Therapy in Combination with Basal Insulin

Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Aug 11, 2023

Primary completion

Jul 13, 2024

Study completion Aug 8, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the efficacy, safety, and tolerability of once-weekly GZR4 Injection versus once-daily insulin degludec in patients with type 2 diabetes mellitus in inadquete control on oral antidiabetic drug (OAD) therapy or OAD Therapy in combination with basal insulin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • GZR4 InjectionDrug

    GZR4 injection s.c., once-weekly, treat-to-target dose

  • Insulin DegludecDrug

    Insulin Degludec s.c., once-daily, treat-to-target dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: From baseline (week 0) to week 16

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site 02

    Beijing, China

  • Study Site 05

    Beijing, China

  • Study Site 01

    Tianjin, China

  • Study Site 07

    Wuhan, Hubei, China

  • Study Site 06

    Changzhou, Jiangsu, China

  • Study Site 08

    Jinan, Shandong, China

  • Study Site 04

    Zibo, Shandong, China

  • Study Site 03

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.